Premium
The value of long‐term protocol biopsies after kidney transplantation
Author(s) -
Tanabe Tatsu
Publication year - 2014
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/nep.12253
Subject(s) - subclinical infection , medicine , calcineurin , immunosuppression , biopsy , chronic allograft nephropathy , transplantation , kidney transplantation , nephrotoxicity , nephropathy , glomerulonephritis , urology , kidney , endocrinology , diabetes mellitus
Protocol biopsies for the detection and treatment of subclinical rejection in the early period after kidney transplantation are useful for preventing allograft dysfunction. However, little has been reported on the relationship between subclinical rejection and long‐term protocol biopsies. In this review, we examine the potential benefits associated with long‐term allograft biopsies focusing on the issue of immunological and non‐immunological factors. Early detection and treatment of subclinical rejection improves outcome. However, the benefit of long‐term allograft biopsies is largely unproved, and the strategy is yet to be widely implemented. The procurement of long‐term protocol biopsies for the sole purpose of detecting subclinical rejection may be unwarranted. On the other hand, the early detection of IgA nephropathy using long‐term protocol biopsy may improve graft survival. In addition, assessment of long‐term protocol biopsies is useful not only for detection of calcineurin inhibitor nephrotoxicity, but also for follow‐up after withdrawal of calcineurin inhibitor regimens. Also, identifying normal histology on a protocol biopsy may inform us about the safety of reducing overall immunosuppression. Thus, the potential benefit of long‐term protocol biopsy may be of clinical significance for the detection of graft dysfunction as a result of non‐immune factors, such as recurrence of glomerulonephritis and calcineurin inhibitor nephrotoxicity, rather than subclinical rejection.